Recovery Blueprint: Mifepristone Access and Standing Doctrine

The Structural Problem

The Supreme Court's decision to maintain broader access to mifepristone while the legal challenge continues reveals a fundamental design flaw: the federal judiciary lacks adequate structural barriers to prevent speculative third-party challenges to agency scientific determinations. The Alliance for Hippocratic Medicine and affiliated physicians sued the FDA not because they prescribed mifepristone or faced regulatory consequences, but because they objected to the agency's expansion of access protocols established over two decades ago.

The Court ultimately dismissed the case on standing grounds, finding plaintiffs lacked sufficient injury. But the litigation reached the nation's highest court, consumed years of regulatory uncertainty, and temporarily restricted access through lower court injunctions—all despite plaintiffs having no direct relationship to the challenged agency action. The problem is not that courts reviewed FDA decisions; judicial review is constitutionally appropriate. The problem is that Article III standing doctrine, as currently constructed, permits lawsuits by parties whose connection to agency actions is so attenuated that the litigation becomes a vehicle for policy disagreement rather than concrete dispute resolution.

Root Cause: Justiciability Without Boundaries

The structural gap lies in the ambiguity of injury-in-fact requirements for challenges to regulatory agency decisions. Current standing doctrine requires plaintiffs demonstrate (1) concrete and particularized injury, (2) causation, and (3) redressability. But courts have inconsistently applied these requirements to challenges against agency approvals of drugs, devices, and other products, creating a justiciability window wide enough to permit third parties with ideological objections to impose years of litigation uncertainty on scientific regulatory processes.

The FDA operates under statutory authority to approve drugs based on safety and efficacy determinations. Once approved, those determinations carry presumptive validity unless overturned through administrative procedures or judicial review initiated by parties with cognizable legal injury. The design flaw is that "injury" has been construed broadly enough to include speculative chains of causation—physicians claiming they might someday encounter complications from a drug they don't prescribe, administered by providers they don't supervise, to patients they've never met.

This is not a problem of judicial philosophy or political capture. It is a problem of insufficient structural definition in the justiciability threshold that guards access to federal courts for regulatory challenges.

Calibration One: Statutory Standing Limitations for Third-Party Regulatory Challenges

Congress should amend the Administrative Procedure Act (5 U.S.C. § 702) to establish explicit standing requirements for challenges to agency product approvals. The amendment would require plaintiffs challenging FDA drug approvals to demonstrate either: (1) direct regulatory burden (they are prohibited from, compelled to, or penalized for specific conduct); (2) competitive injury (they are market participants directly harmed by the approval); or (3) procedural injury (they participated in the administrative process and suffered denial of a statutory right).

This Calibration closes the gap by codifying what injury-in-fact means in the regulatory approval context. It does not eliminate judicial review—parties with concrete stake remain protected. It eliminates the structural vulnerability that allows litigation to function as disguised policy advocacy. Congress possesses clear authority under Article III to define the scope of federal jurisdiction and has exercised this authority repeatedly in other statutory schemes.

The repair: before this change, standing doctrine relies on judge-made common law with inconsistent application. After this change, federal courts apply congressionally defined thresholds that require direct nexus between plaintiff and challenged action.

Calibration Two: Interlocutory Injunction Standards for Agency Scientific Determinations

Federal courts should adopt—either through Supreme Court precedent or Federal Rules of Civil Procedure amendment—heightened standards for preliminary injunctions against agency actions rooted in scientific or technical findings. The current standard requires plaintiffs show likelihood of success, irreparable harm, balance of equities, and public interest. For challenges to agency scientific determinations (drug approvals, environmental assessments, safety evaluations), courts should be required to defer unless plaintiffs demonstrate the agency action was arbitrary and capricious by clear and convincing evidence at the preliminary stage.

Lower courts issued injunctions restricting mifepristone access despite FDA's 23-year regulatory history and extensive safety data. The structural problem is that preliminary injunction standards treat all agency actions identically, whether ministerial decisions or complex scientific judgments developed through years of expert evaluation and public comment.

This Calibration creates a procedural speed bump. It acknowledges that injunctions against scientific agency determinations impose systemic costs—regulatory uncertainty, chilled agency action, disrupted reliance interests—that warrant heightened showing requirements. The Supreme Court or the Judicial Conference's Advisory Committee on Civil Rules holds implementation authority.

The repair: before, district courts apply uniform injunction standards regardless of agency action type. After, courts must account for the institutional competence gap and reliance interests involved in scientific regulatory determinations.

Calibration Three: Statutory Finality for Time-Tested Approvals

Congress should amend the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.) to establish a safe harbor for drug approvals maintained without significant adverse safety findings for 15 years or longer. After this threshold, challenges to the original approval decision would be barred; plaintiffs could only challenge new agency actions modifying access protocols or could petition the FDA to withdraw approval based on new safety evidence.

Mifepristone was approved in 2000. The 2024 legal challenge contested not new FDA decisions but the foundational approval itself, decades later. This reveals a structural absurdity: no regulatory determination ever achieves finality. Agencies face perpetual exposure to relitigation of decades-old scientific conclusions by parties who emerged long after the administrative process concluded.

This Calibration installs a structural sunset on challenges to the original approval, while preserving avenues to address new safety concerns and challenge new agency modifications. It creates actual finality, which agencies need to function and regulated parties need to invest and plan. Congress has clear authority over drug approval frameworks.

The repair: before, any approval remains perpetually vulnerable to facial challenge regardless of longevity or safety record. After, approvals achieve finality after demonstrating extended safety performance, with ongoing accountability through withdrawal petitions and challenges to new modifications.

Minimum Viable Repair

Of the three Calibrations, the first—statutory standing requirements—is most achievable and most essential. It addresses the root access point that permits the cascade of downstream problems. Without structural standing limitations, agencies face endless speculative litigation, courts must resolve scientific questions beyond institutional competence, and regulatory beneficiaries endure needless uncertainty.

The minimum repair needed to prevent cascade failure: Congress must define injury-in-fact for regulatory approval challenges with sufficient precision to exclude third parties whose only stake is policy disagreement. The alternative is a federal judiciary that functions as ongoing plebiscite on agency scientific determinations, decided by whoever finds a creative theory of speculative harm and a receptive district court.